



Universiteit
Leiden
The Netherlands

Germline variants in the mismatch repair genes: Detection and phenotype

Suerink, M.

Citation

Suerink, M. (2021, March 3). *Germline variants in the mismatch repair genes: Detection and phenotype*. Retrieved from <https://hdl.handle.net/1887/3147165>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3147165>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/3147165> holds various files of this Leiden University dissertation.

Author: Suerink, M.

Title: Germline variants in the mismatch repair genes: Detection and phenotype

Issue date: 2021-03-03



Incidence of (adenomatous) polyps and colorectal cancer in patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis

Manuscript in preparation

Sanne W. ten Broeke[#], Manon Suerink[#], Diantha Terlouw, Alexandra M.J. Langers, Eveline Dekker, Carli M.J. Tops, Hans F.A. Vasen, Tom van Wezel, Hans Morreau, Maartje Nielsen, on behalf of the PALGA-group and the Dutch working group for clinical oncogenetics

[#] These authors contributed equally to this work.

ABSTRACT

Purpose

Lynch syndrome predisposes carriers of a heterozygous pathogenic germline variant in the *MLH1*, *MSH2*, *MSH6* or *PMS2* genes to the development of mainly colorectal (CRC) and endometrial cancer. Of the four mismatch repair (MMR) genes, *PMS2* variant carriers have the lowest cancer risk, yet surveillance protocols are identical for all Lynch syndrome patients. The aim of this study was to determine the characteristics and incidence of polyps and incident CRC in *PMS2* variant carriers undergoing regular surveillance.

Methods

We collected a cohort of 171 *PMS2* variant carriers and recorded the occurrence and characteristics of incident adenomas and CRC. After receiving consent to request clinical data, we obtained information through PALGA, the Dutch nationwide network and registry of histo- and cytopathology, and by requesting colonoscopy reports at gastroenterology departments. Twenty polyps were available for immunohistochemical staining of the *PMS2* protein.

Results

During a total of 675 colonoscopies (1044 observation years, median surveillance interval 2 years), 435 polyps were removed, of which 237 (54.5%) were adenomatous. Forty-one (16.9%) of those adenomas were advanced (i.e. ≥ 1 cm in diameter, villous component and/or high-grade dysplasia). None of the twenty polyps that were immunohistochemically stained showed loss of *PMS2* expression, suggesting late involvement of *PMS2* deficiency in the pathway to cancer. One incident CRC was reported.

Conclusion

In this large cohort of *PMS2* variant carriers, only one incident CRC were observed. This tumor was preceded by a colonoscopy with insufficient bowel preparation. Further analyses are required to draw firm conclusions about adenoma risk in *PMS2* carriers compared to the other MMR genes.

INTRODUCTION

Lynch syndrome predisposes carriers of a germline heterozygous pathogenic variant in one of the mismatch repair genes (MMR): *MLH1*, *MSH2*, *MSH6* or *PMS2*, to the development of mainly colorectal and endometrial cancer. Lynch syndrome-associated cancers are characterized by microsatellite instability (MSI) and negative immunohistochemical staining for the involved MMR protein.^{1,2} To prevent the development of colorectal cancer, patients with Lynch syndrome are offered surveillance by colonoscopy every 1-2 years, starting at age 25.³ Despite these regular surveillance colonoscopies, incident colorectal cancers do occur, particularly in *MLH1* and *MSH2* variant carriers.^{4,7} Data on polyps and incident colorectal cancer in PMS2-associated Lynch syndrome is sparse, yet highly clinically relevant since recent studies reported a high prevalence of *PMS2* variants in the general population (1:714).⁸ *PMS2* variant carriers display a distinct phenotype, with retrospective cohort studies reporting substantially lower cancer risks compared to carriers of *MLH1* and *MSH2* variants,^{9,11} which has resulted in discussion of MMR-gene-specific surveillance protocols.⁴ This discussion would be greatly assisted by more prospectively collected gene-specific data. Previously, the prospective Lynch syndrome database (PLSD) consortium has confirmed low cancer risks for carriers of pathogenic variants in the *PMS2* gene.^{4,12-14} However, these studies did not include exact data on endoscopic detection of adenomas, which is essential for a better understanding of the role of MMR deficiency in Lynch syndrome associated carcinogenesis. Moreover, data on quality of surveillance is usually also lacking. To this aim, we collected prospective colonoscopy data on a large cohort of *PMS2* variant carriers (n=171) and evaluated *PMS2* protein expression in twenty polyps.

MATERIALS & METHODS

Data collection

Consent was obtained to request clinical information and pathology samples for 186 Dutch Lynch syndrome patients with a confirmed pathogenic germline *PMS2* variant diagnosed at Dutch family cancer clinics. Obtaining pathology reports was facilitated by PALGA, the nationwide network and registry of histology and cytopathology in the Netherlands.¹⁵ As PALGA encompasses all pathology laboratories in the Netherlands, all pathology reports on each patient can be obtained, even if a patient attended different hospitals for colonoscopies. Corresponding colonoscopy reports were

requested at the respective gastroenterology departments. For fourteen *PMS2* variant carriers both the PALGA search and request for colonoscopy reports did not yield any results, therefore these patients most likely are not undergoing regular surveillance and they were excluded from the analyses. Furthermore, one patient was excluded from the analyses, because of an exceptionally severe phenotype (three synchronous colorectal cancers and 18 adenomas at age 26 and an intellectual disability). This extraordinary phenotype is likely not completely explained by his *PMS2* variant alone. The study was approved by the IRB of the LUMC.

PMS2 variant analysis

Our cohort consisted of clinically ascertained families in which variant analysis was initiated because a family met the Bethesda criteria¹⁶ and/or (histological) pre-screening by immunohistochemistry and/or microsatellite instability was indicative of MMR deficiency. Germline *PMS2* variant screening was performed as previously described.^{10,11,17} Comprehensive strategies were applied to avoid unreliable variant detection caused by interference from pseudogene sequences and frequent gene conversion events.¹⁷ All variants found in the included *PMS2* carriers are listed in supplemental tables 1 and 2.

Immunohistochemistry

We retrieved formalin-fixed, paraffin-embedded (FFPE) tissue blocks of 16 adenomas with low-grade dysplasia (one of which was scored as advanced because of a villous component), two sessile serrated lesions and two hyperplastic polyps, and performed immunohistochemical analysis of *PMS2* expression. In brief, the FFPE material was sectioned at 4 μm and stained with an antibody to *PMS2* (Clone EP51, Agilent, Santa Clara, CA, USA). If the staining results showed absence of nuclear staining in the cells of an adenoma or polyp in the presence of positive control cells (e.g. leukocytes) than this was interpreted as *PMS2* deficiency.

Statistical analysis

Descriptive results of colonoscopy findings were computed using Stata (Statacorp version 14). A Kaplan Meier analysis was carried out to estimate time to first adenoma or first (advanced) adenoma. Timepoint zero was the time at first colonoscopy. Advanced adenomas were defined by a size of ≥ 1 cm in diameter, a villous component of $>25\%$, and/or the presence of high-grade dysplasia.

Results were compared to data from two studies. One study by Engel et al. which reports the occurrence of incident adenomas and advanced adenomas in a large

cohort of *MLH1*-, *MSH2*-, and *MSH6*-associated Lynch syndrome patients.¹⁸ Forsberg et al. report more detailed data on histological subtypes and numbers of (adenomatous) polyps at first colonoscopy in a cohort of *MLH1*-, *MSH2*-, and *MSH6*-associated Lynch syndrome patients and compare this data to control data from an earlier prospective population-based colonoscopy study by the same group.¹⁹

RESULTS

Between 1987 and 2017, a total of 675 colonoscopies were performed in this cohort of 171 *PMS2* variant carriers, representing 1044 years of follow-up. The median time between follow-up colonoscopies was 2.0 years. All included *PMS2*-associated Lynch syndrome patients had a confirmed germline heterozygous pathogenic variant in the *PMS2* gene (supplemental material) and all have been described in previous studies.^{10,11,17,20} A detailed description of the cohort is provided in table 1.

Polyps

In total, 435 polyps were removed from 171 *PMS2* variant carriers, half of which were adenomatous (54.5%). Figure 1 shows the cumulative risk of developing an adenoma after the first colonoscopy. The risk of developing an adenoma is 54.5% (95% CI 41.4 – 68.8%) after 10 years. This is higher than the risks reported for carriers of a mutation in the other genes as reported by Engel et al (44.2% for *MSH2*, 38.4% for *MSH6* and 32.2% for *MLH1*).¹⁸

Figure 2 shows the cumulative risk of developing an advanced adenoma after first colonoscopy, which was 23.7% (95% CI 12.3 – 43.0%) after 10 years. This risks appears to be higher than for carriers of a pathogenic variant in the other genes as reported by Engel et al.¹⁸ However, because of a wide confidence interval, no reliable comparison can be made.

When comparing the cumulative proportion of individuals with an adenoma at first colonoscopy as a function of age between our *PMS2* cohort (supplemental figure 1) and the cohorts as published by Forsberg et al.²¹, the *PMS2* cohort shows a lower adenoma risk than the Forsberg Lynch cohort, but a higher risk than the Forsberg control cohort. The same can be said for the cumulative proportion of advanced adenomas (supplemental figure 2).

The sixteen adenomas with low-grade dysplasia, two sessile serrated lesions and two hyperplastic polyps stained for *PMS2* protein expression showed normal staining (table 2).

Chapter 8

Table 1. Cohort characteristics

	PMS2 cohort	MLH1 (Engel et al)	MSH2 (Engel et al)	MSH6 (Engel et al)
Patients	171	1407	986	354
Men	69 (40.4%)	47.8%	49%	45.2%
Follow-up (years)				
Total	1044	12798	7961	2550
Mean (s.d.)	6.1 (5.9)			
Median (IQR)	4.2 (1.7-9.0)	8.5 (4.2-13.2)	7.4 (4.4-11.3)	6.5 (4.1-9.4)
Range	0-28.4			
Colonoscopies				
Total	675	8299	6300	1798
Number per patient				
Mean (s.d.)	3.9 (3.0)			
Median (IQR)	3 (1-5)	5 (3-8)	6 (4-8)	4 (3-6)
Range	1-18			
Time interval (years)\$				
Mean (s.d.)	2.1 (1.9)			
Median (IQR)	2.0 (1.1-2.2)			
Range	0.02-22.5			
Mean age first colonoscopy (s.d.)	50.6 (12.9)	42.7 (13.5)	44.0 (12.3)	48.7 (13.7)
Mean age first adenoma detected (s.d.)	55.3 (12.5)			
Mean age first advanced adenoma detected (s.d.)	56.8 (13.1)			
Total polyps	435			
Hyperplastic polyps	181 (41.6%)			
Location				
Right-sided	52 (28.7%)			
Left sided	111 (61.3%)			
Not specified	18 (9.9%)			
Sessile serrated polyps/adenomas*	16 (3.7%)			
Location left-sided				
Right-sided	8 (50%)			
Left sided	8 (50%)			
Not specified	0			
Mixed	1 (0.2%)			
Adenomas	237 (54.5%)			
Histology				
Tubular adenoma	154 (65%)			
Tubulovillous adenoma	23 (9.7%)			
Villous adenoma	1 (0.4%)			
Sessile serrated adenoma with dysplasia	12 (5.1%)			
Adenoma n.o.s.	47 (19.8%)			

Incidence of (adenomatous) polyps and colorectal cancer in patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis

	PMS2 cohort	MLH1 (Engel et al)	MSH2 (Engel et al)	MSH6 (Engel et al)
Size (mm)				
0-4	134 (56.5%)			
5-10	50 (21.1%)			
10<	21 (8.9%)			
Not specified	32 (13.5%)			
Location				
Right-sided	92 (38.8%)			
Left sided	120 (50.6%)			
Not specified	25 (10.6%)			
Dysplasia				
None	1 (0.4%)			
High grade	6 (2.5%)			
Low grade	222 (93.7%)			
Not specified	8 (3.4%)			
Advanced	41 (16.9%)			

n.o.s.: not otherwise specified, IQR: Interquartile range; s.d.: Standard deviation

Advanced: adenomas ≥ 1 cm in diameter, villous component, and/or high-grade dysplasia

\$ only if >1 colonoscopy was performed

* Sessile serrated adenomas were listed in this category if there was no dysplasia




Figure 1 Cumulative proportion of *PMS2* carriers with an adenoma since start of colonoscopy ($t=0$) with 95% confidence intervals




Figure 2 Cumulative incidence of advanced adenomas in *PMS2* carriers with 95% confidence intervals, t=0 is first colonoscopy.

Chapter 8

Table 2. Polyps stained for PMS2 protein expression
n.a.: not applicable; n.o.s.: not otherwise specified; CRC: colorectal cancer

Case ID	Gender	CRC	Cumulative number of adenomas	Age of diagnosis first adenoma (years)	Cumulative number of hyperplastic polyps	Cumulative No of sessile serrated lesions	Polyp ID	Site of adenoma	Histology	Grade of Dysplasia	Size (mm)	PMS2 IHC
1	F	No	3	62	1	0	1.1	Right	Tubulovillous adenoma	Low	5	+
							1.2	Left	Tubular adenoma	Low	3	+
2	F	Yes	2	67	23	5	2.1	Pouch	Sessile serrated adenoma	Low	3	+
							2.2	Left	Mixed adenoma	Low	2	+
							2.3	Right	Tubular adenoma	Low	3	+
							2.4	Colon n.o.s.	Hyperplastic polyp	n.a.	8	+
3	F	No	6	57	2	0	3.1	Right	Tubular adenoma	Low	2	+
							3.2	Right	Adenomatous n.o.s.	Low	2,5	+
4	F	No	3	61	0	1	4.1	Right	Tubular adenoma	Low	2	+
							4.2	Left	Tubular adenoma	Low	3	+
							4.3	Left	Sessile serrated polyp	None	10	+
							4.4	Left	Tubular adenoma	Low	2	+
5	M	Yes	3	54	1	0	5.1	Left	Tubular adenoma	Low	2	+
6	F	No	1	45	0	0	6.1	Right	Adenomatous n.o.s.	Low	2	+
7	F	Yes	2	28	1	0	7.1	Left	Adenomatous n.o.s.	Low	3	+
8	M	Yes	15	64	0	0	8.1	Right	Adenomatous n.o.s.	Low	2	+
							8.2	Right	Tubular adenoma	Low	5	+
							8.3	Right	Adenomatous n.o.s.	Low	3	+
9	F	No	1	42	0	0	9.1	Colon n.o.s.	Tubular adenoma	Low	3	+
10	F	Yes	3	76	5	0	10.1	Colon n.o.s.	Hyperplastic polyp	n.a.	5	+

One *PMS2* variant carrier developed an incident colorectal cancer despite undergoing biennial regular colonoscopic surveillance (table 3). The patient presented with colorectal cancer at age 65, was diagnosed with Lynch syndrome, and had a subsequent incident colorectal cancer at age 75. However, this patient had a record of incomplete colonoscopies due to insufficient bowel cleansing, including the colonoscopy preceding the colorectal cancer. The tumor was immunohistochemically stained for MMR protein expression which revealed absent PMS2 staining, as did the initial tumor.

Table 3. *PMS2* carrier with an incident CRC

Sex	Male
Surveillance scopies	10
Years of surveillance	11
Time since last scopy before incident CRC	2 years
Findings at last scopy/clinical evaluation before incident CRC	No adenomas were removed during colonoscopy. There was poor bowel preparation. One adenoma with low grade dysplasia was removed from the stoma of the patient.
Initial CRC	
Age	65
Location	Rectum
IHC	PMS2-
MSI	MSI-H
Incident CRC	
Age	75
Location	Transverse colon
IHC PMS2	Absent
MSI	NA

CRC: colorectal cancer; MSI: Microsatellite instability; IHC: Immunohistochemistry

DISCUSSION

PMS2-associated Lynch syndrome is characterized by relatively low penetrance of colorectal cancer, both in retrospective cohorts of patients who are not under surveillance, as well as in prospective cohorts where patients receive regular colonoscopies.^{10,11,22-24} Our study confirms the very low risk for colorectal cancer in *PMS2* variant carriers who undergo regular colonoscopic surveillance. Recent studies have shown that MMR deficient (MMR-d) colorectal cancer in Lynch syndrome patients may develop not only through the traditional MMR proficient (MMR-p) adenoma-to-colorectal cancer progression pathway, but may also arise from the MMR-d crypt pathway.²⁵⁻²⁸ Tumors arising via this latter pathway directly proceed from MMR-d crypt to cancer or can first develop into an MMR-d adenoma before becoming malignant.^{26,27} The cancers that develop directly from an MMR-d crypt lack a benign precursor lesion and cannot be prevented by colonoscopies. Clinically, these tumors may appear as incident colorectal cancer (i.e. tumors that develop between protocolized follow-up surveillance colonoscopies).²⁶ Recent work by our group suggests that the MMR-d crypt pathway may be absent in *PMS2* variant carriers.²⁹ This finding, combined with previous reports that colorectal cancer in non-*PMS2* MMR variant carriers develops through the MMR-d crypt pathway, may explain the low penetrance observed in *PMS2* variant carriers, particularly those under surveillance.^{10,11,22,23,27,30} This is in line with our current observation of only one incident cancer. This, combined with normal *PMS2* staining in all analyzed adenomas, supports the hypothesis that *PMS2* carriers only develop colorectal cancer through the MMR-p adenoma pathway. In this pathway *PMS2* deficiency may occur as a relatively late event in (advanced) adenomas, which could then stimulate the malignant transformation. If we assume that this is the only pathway that occurs in these Lynch syndrome patients, it is conceivable that the most important risk factor for colorectal cancer in *PMS2* variant carriers is actually adenoma formation. Indeed, as the *PMS2* variant carriers included in this study were members of families ascertained by high-risk family cancer clinics, our cohort may have been enriched for adenoma risk factors. The observation that the (advanced) adenoma risk at first colonoscopy in our cohort lies between the Forsberg Lynch cohort (which consists of *MLH1*, *MSH2* and *MSH6* carriers) and their control cohort may well be an illustration of this.²¹

When comparing the cumulative 10-year adenoma risk as reported by Engel *et al.*¹⁸, a higher adenoma risk is seen in our cohort compared to the other MMR genes. Engel *et al.* hypothesize that *MLH1* carriers mainly develop cancer through the MMR-d crypt pathway, *MSH2* carriers through quick progression of an MMR-d adenoma into

a carcinoma and *MSH6* carriers through the MMR-p adenoma-carcinoma pathway. The retained PMS2 expression in the adenomas and previous published data on somatic mutation patterns in *PMS2* associated colorectal cancers,³¹ suggest that the predominant pathway to colorectal cancer in *PMS2* carriers is similar to *MSH6* and involves the MMR-p adenoma-carcinoma pathway. However, it is surprising that a high 10-year risk of adenoma development is identified in our cohort. As suggested before, a possible explanation for the relatively high prevalence of adenomas is enrichment for adenoma risk factors in clinically ascertained *PMS2* families. However, interpretation of the comparison of adenoma risks is complicated by the differences in mean age at first colonoscopy between our cohort (50.6 years) compared to the cohort of Engel et al. where it is 42.7 years for *MLH1*, 44.0 years for *MSH2* and 48.7 years in *MSH6*. When factoring in age, a higher risk of adenoma development was noted with increasing age within our own cohort (data not shown), but additional analyses will have to show how much of the difference between the cohorts can be explained by age.

It is striking that different conclusions are drawn when comparing our cohort to two different studies (*i.e.* a relatively low number of adenomas at first colonoscopy compared to the Lynch families as described by Forsberg et al.²¹ and a relatively high 10-year adenoma risk as compared to the Lynch syndrome patients as reported by Engel et al.¹⁸). Because both studies apply different analyses methods, at this moment it is not possible to find out whether these differences can be attributed to the different approaches in data analysis.

Future studies should investigate the influence of known adenoma risk factors in *PMS2* families, such as obesity and smoking, as this may be important in further decreasing colorectal cancer risk in *PMS2* variant carriers.^{32,33} If indeed colorectal cancer development in *PMS2* variant carriers can mostly be prevented by regular surveillance and polypectomies, we would expect a very low cancer risk in this prospective cohort. Nevertheless, we did observe one incident colorectal cancer in our cohort, a finding that on closer inspection of colonoscopy reports appeared to be related to insufficient bowel preparation in this carrier (table 3), highlighting the need for high quality colonoscopy with good bowel preparation to prevent incident colorectal cancer.³⁴

Future studies should include a larger number of both tumors and (advanced) adenomas for immunohistochemical staining. Further studies should also elaborate on molecular analysis of, for example, *APC* and *CTNNB1* variants, as specific variants in these genes can help identify the timing of MMR deficiency, as previously shown in the study by Ahadova et al.²⁷ and Engel et al.¹⁸ This approach might ultimately provide definitive proof of the late involvement of PMS2 deficiency.

Chapter 8

In summary, we confirm that *PMS2* variant carriers undergoing regular surveillance colonoscopies are at very low risk for colorectal cancer. This finding supports previous proposals for a less intensive surveillance protocol in these Lynch patients, for example every 2-3 years, starting at age 35-40 years. Comparison of *PMS2* adenoma risk to the adenoma risk in other MMR gene variant carriers is complicated by differences in cohort characteristics and analyses methods between our study and previous publications and requires further investigation.

REFERENCES

1. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. *Journal of Molecular Diagnostics*. 2008;10(4):293-300.
2. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. *Journal of Molecular Diagnostics*. 2008;10(4):301-307.
3. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Laloo F, Lindblom A, Mecklin JP, Moller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de LM, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Jarvinen HJ, Moslein G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut*. 2013;62(6):812-823.
4. Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F, Blanco I, Sijmons RH, Jeffries J, Vasen HFA, Burn J, Nakken S, Hovig E, Rodland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen JT, Jenkins MA, Green K, Laloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Valentin MD, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moeslein G, Sampson JR, Capella G, Mallorca G. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2017.
5. Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, Koornstra JJ, Boot H, Cats A, Dekker E, Sanduleanu S, Poley JW, Hardwick JC, de Vos Tot Nederveen Cappel WH, van der Meulen-de Jong AE, Tan TG, Jacobs MA, Mohamed FL, de Boer SY, van de Meeberg PC, Verhulst ML, Salemans JM, van Bentem N, Westerveld BD, Vecht J, Nagengast FM. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology*. 2010;138(7):2300-2306.
6. Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM. Rapid development of colorectal neoplasia in patients with Lynch syndrome. *Clinical Gastroenterology and Hepatology*. 2011;9(4):340-343.
7. Engel C, Rahner N, Schulmann K, Holinski-Feder E, Goecke TO, Schackert HK, Kloor M, Steinke V, Vogelsang H, Moslein G, Gorgens H, Dechant S, von Knebel Doeberitz M, Ruschoff J, Friedrichs N, Buttner R, Loeffler M, Propping P, Schmiegel W, German HC. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clinical Gastroenterology and Hepatology*. 2010;8(2):174-182.
8. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, Buchanan DD, Clendenning M, Rosty C, Ahnen DJ, Thibodeau SN, Casey G, Gallinger S, Le Marchand L, Haile RW, Potter JD, Zheng Y, Lindor NM, Newcomb PA, Hopper JL, MacInnis RJ. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 2017;26(3):404-412.
9. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology*. 2008;135(2):419-428.
10. ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuisen ME, Bernstein I, Capella Munar G, Gomez Garcia E, Hoogerbrugge N, Letteboer TG, Menko FH, Lindblom A, Mensenkamp AR, Moller P, van Os TA, Rahner N, Redeker BJ, Sijmons RH, Spruijt L, Suerink M, Vos YJ, Wagner A, Hes FJ, Vasen HF, Nielsen M, Wijnen JT. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. *J Clin Oncol*. 2015;33(4):319-325.


11. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, de la Chapelle A, Capella G, Clendenning M, Engel C, Gallinger S, Gomez Garcia E, Figueiredo JC, Haile R, Hampel HL, Hopper JL, Hoogerbrugge N, von Knebel Doeberitz M, Le Marchand L, Letteboer TGW, Jenkins MA, Lindblom A, Lindor NM, Mensenkamp AR, Moller P, Newcomb PA, van Os TAM, Pearlman R, Pineda M, Rahner N, Redeker EJW, Olderode-Berends MJW, Rosty C, Schackert HK, Scott R, Senter L, Spruijt L, Steinke-Lange V, Suerink M, Thibodeau S, Vos YJ, Wagner A, Winship I, Hes FJ, Vasen HFA, Wijnen JT, Nielsen M, Win AK. Cancer Risks for PMS2-Associated Lynch Syndrome. *J Clin Oncol*. 2018;36(29):2961-2968.
12. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rodland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moslein G, Sampson JR, Capella G, Mallorca G. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut*. 2017;66(9):1657-1664.
13. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rodland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Sampson JR, Capella G, Mecklin JP, Moslein G, Mallorca G. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017;66(3):464-472.
14. Dominguez-Valentin M, Sampson JR, Seppala TT, Ten Broeke SW, Plazzer JP, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Kostner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Buttner R, Gorgens H, Holinski-Feder E, Morak M, Holzapfel S, Huneburg R, Knebel Doeberitz MV, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvanainen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sanchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rodland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Moslein G, Mecklin JP, Nielsen M, Moller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genetics in Medicine*. 2019.
15. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cellular Oncology*. 2007;29(1):19-24.
16. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. 2004;96(4):261-268.
17. van der Klift HM, Mensenkamp AR, Drost M, Bik EC, Vos YJ, Gille HJ, Redeker BE, Tiersma Y, Zonneveld JB, Garcia EG, Letteboer TG, Olderode-Berends MJ, van Hest LP, van Os TA, Verhoef S, Wagner A, van Asperen CJ, Ten Broeke SW, Hes FJ, de Wind N, Nielsen M, Devilee P, Ligtenberg MJ, Wijnen JT, Tops CM. Comprehensive Mutation Analysis of PMS2 in

- a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome. *Hum Mutat.* 2016.
18. Engel C, Ahadova A, Seppala TT, Aretz S, Bigirwamungu-Bargeman M, Blaker H, Bucksch K, Buttner R, de Vos Tot Nederveen Cappel WT, Endris V, Holinski-Feder E, Holzapfel S, Huneburg R, Jacobs M, Koornstra JJ, Langers AM, Lepisto A, Morak M, Moslein G, Peltomaki P, Pylvanainen K, Rahner N, Renkonen-Sinisalo L, Schulmann K, Steinke-Lange V, Stenzinger A, Strassburg CP, van de Meeberg PC, van Kouwen M, van Leerdam M, Vangala DB, Vecht J, Verhulst ML, von Knebel Doeberitz M, Weitz J, Zachariae S, Loeffler M, Mecklin JP, Kloor M, Vasen HF, German Hnpcc Consortium tDLSCG, Finnish Lynch Syndrome R. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. *Gastroenterology.* 2020;158(5):1326-1333.
 19. Forsberg AM, Kjellstrom L, Agreus L, Nixon Andreasson A, Nyhlin H, Talley NJ, Bjorck E. Prevalence of colonic neoplasia and advanced lesions in the normal population: a prospective population-based colonoscopy study. *Scandinavian Journal of Gastroenterology.* 2012;47(2):184-190.
 20. Ten Broeke SW, Elsayed FA, Pagan L, Olderode-Berends MJW, Garcia EG, Gille HJP, van Hest LP, Letteboer TGW, van der Kolk LE, Mensenkamp AR, van Os TA, Spruijt L, Redeker BJW, Suerink M, Vos YJ, Wagner A, Wijnen JT, Steyerberg EW, Tops CMJ, van Wezel T, Nielsen M. SNP association study in PMS2-associated Lynch syndrome. *Fam Cancer.* 2017.
 21. Forsberg A, Kjellstrom L, Andreasson A, Jaramillo E, Rubio CA, Bjorck E, Agreus L, Talley NJ, Lindblom A. Colonoscopy findings in high-risk individuals compared to an average-risk control population. *Scandinavian Journal of Gastroenterology.* 2015;50(7):866-874.
 22. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology.* 2008;135(2):419-428.
 23. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. *Genet Med.* 2016;18(1):13-19.
 24. Suerink M, Rodriguez-Girondo M, van der Klift HM, Colas C, Brugieres L, Lavoine N, Jongmans M, Munar GC, Evans DG, Farrell MP, Genuardi M, Goldberg Y, Gomez-Garcia E, Heinimann K, Hoell JI, Aretz S, Jaspersen KW, Kedar I, Modi MB, Nikolaev S, van Os TAM, Ripperger T, Rueda D, Senter L, Sijns W, Sunde L, Therkildsen C, Tibiletti MG, Trainer AH, Vos YJ, Wagner A, Winship I, Wimmer K, Zimmermann SY, Vasen HF, van Asperen CJ, Houwing-Duistermaat JJ, Ten Broeke SW, Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. *Genetics in Medicine.* 2019.
 25. Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, von Knebel Doeberitz M, Blaker H. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. *Lancet Oncol.* 2012;13(6):598-606.
 26. Ahadova A, von Knebel Doeberitz M, Blaker H, Kloor M. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. *Familial Cancer.* 2016;15(4):579-586.
 27. Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, Stenzinger A, Burn J, von Knebel Doeberitz M, Blaker H, Kloor M. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. *Int J Cancer.* 2018.
 28. Staffa L, Echterdiek F, Nelius N, Benner A, Werft W, Lahrmann B, Grabe N, Schneider M, Tariverdian M, von Knebel Doeberitz M, Blaker H, Kloor M. Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters. *PLoS One.* 2015;10(3):e0121980.


Chapter 8

29. Ten Broeke SW, van Bavel TC, Jansen AML, Gomez-Garcia E, Hes FJ, van Hest LP, Letteboer TGW, Olderode-Berends MJW, Ruano D, Spruijt L, Suerink M, Tops CM, van Eijk R, Morreau H, van Wezel T, Nielsen M. Molecular Background of Colorectal Tumors From Patients with Lynch Syndrome Associated With Germline Variants in PMS2. *Gastroenterology*. 2018.
30. Sekine S, Mori T, Ogawa R, Tanaka M, Yoshida H, Taniguchi H, Nakajima T, Sugano K, Yoshida T, Kato M, Furukawa E, Ochiai A, Hiraoka N. Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis. *Mod Pathol*. 2017;30(8):1144-1151.
31. Ten Broeke SW, van Bavel TC, Jansen AML, Gomez-Garcia E, Hes FJ, van Hest LP, Letteboer TGW, Olderode-Berends MJW, Ruano D, Spruijt L, Suerink M, Tops CM, van Eijk R, Morreau H, van Wezel T, Nielsen M. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2. *Gastroenterology*. 2018;155(3):844-851.
32. Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, Kampman E. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. *Gastroenterology*. 2012;142(2):241-247.
33. Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker JH, Vasen HF, Kampman E. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. *JClinOncol*. 2010;28(28):4346-4353.
34. Rees CJ, Bevan R, Zimmermann-Fraedrich K, Rutter MD, Rex D, Dekker E, Ponchon T, Bretthauer M, Regula J, Saunders B, Hassan C, Bourke MJ, Rosch T. Expert opinions and scientific evidence for colonoscopy key performance indicators. *Gut*. 2016;65(12):2045-2060.

SUPPLEMENTAL INFORMATION



Supplemental Figure 1 Cumulative proportion of *PMS2* carriers with an adenoma at first colonoscopy



Supplemental Figure 2 Cumulative proportion of *PMS2* carriers with an advanced adenoma at first colonoscopy

Incidence of (adenomatous) polyps and colorectal cancer in patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis

Supplementary Table 1. PMS2 variants reported as disease-causing in the families included in this study

exon/ intron	PMS2 variant ^a	predicted protein effect	type of variant	InSiGHT class ^b	No of carriers with variant
2	c.137G>T	p.Ser46Ile	missense	4	4
2	c.24-12_107delinsAAAT	p.Ser8Argfs*5	frameshift	5	4
2	c.150delinsAG	p.Ala51Glyfs*3	frameshift	Not present, reported by clinic as pathogenic	1
3	c.219_220dup	p.Gly74Valfs*3	frameshift	5	12
6	c.697C>T	p.Gln233*	nonsense	5	6
7	c.736_741delinsTGTGTGTGAAG	p.Pro246Cysfs*3	frameshift	5	20
intron 7	c.804-60_804-59insJN866832.1		retrotransposal SVA insertion	5	3
8	c.861_864del	p.Arg287Serfs*19	frameshift	5	3
8	c.903G>T	r.804_903del; p.Tyr268*	exonic splice variant	4	2
intron 10	c.1144+2T>A	p.Glu330_ Glu381del	canonical splice variant	4	1
11	c.1831dup	p.Ile611Asnfs*2	frameshift	5	5
11	c.1882C>T	p.Arg628*	nonsense	5	21
13	c.2192_2196del	p.Leu731Cysfs*3	frameshift	5	7
14	c.2404C>T ;	p.Arg802*	nonsense	5	1
14	c.2444C>T	p.Ser815Leu	missense	3 (see supp tbl S2)	1
4	c.325dup	p.Glu109Glyfs*30	frameshift	present, not classified (class 5)	5
8	c.823C>T	p.Gln275*	nonsense	present, not classified (class 5)	4
8	c.856_857del	p.Asp286Glnfs*12	frameshift	present, not classified (class 5)	1
11	c.1214C>A	p.Ser405*	nonsense	present, not classified (class 5)	3
12	c.2117del	p.Lys706Serfs*19	frameshift	present, not classified (class 5)	1

Chapter 8

Supplementary Table 1. *PMS2* variants reported as disease-causing in the families included in this study

exon/ intron	PMS2 variant ^a	predicted protein effect	type of variant	InSiGHT class ^b	No of carriers with variant
intron 4	c.354-2A>G		canonical splice variant	not present (class 4)	2
11	c.1237_1238delinsT	p.Lys413*	frameshift	not present (class 5)	1
Intron 13	c.2275+1G>A			Not present, ClinVar class 4/5	1
2	genomic deletion including exon 2		large genomic deletion	5	5
10	genomic deletion including exon 10		large genomic deletion	5	1
14	genomic deletion including exon 14		large genomic deletion	5	10
1_15	genomic deletion whole gene (exons 1-15)		large genomic deletion	5	3
11_12	genomic deletion including exons 11-12		large genomic deletion	5	4
11_15	genomic deletion including exons 11-15		large genomic deletion	5	16
3_7	genomic deletion including exons 3-7		large genomic deletion	5	8
5_15	genomic deletion including exons 5-15		large genomic deletion	5	1
5_7	genomic deletion including exons 5-7		large genomic deletion	5	4
1_11	genomic deletion including exons 1-11		large genomic deletion	5	4
2_4	genomic deletion including exons 2-4		large genomic deletion (in frame)	not present (class 4)	4

^aVariant nomenclature according to HGVS guidelines (<http://varnomen.hgvs.org/>) with reference to NM_000535.5 for *PMS2*, except for large deletions or duplications. Large deletions and duplications were in some cases detected with the older MLPA kit P008 (MRC Holland) that lacks reliable probes for *PMS2* exons 3, 4, 12-15. Therefore, the exact range of exon deletions was not always established. Although for some large deletions the breakpoints have been characterized, we did not include this information.

^bClinical variant class as reported on <https://insight-database.org/variants/PMS2>; last accessed on 14 December 2017; 5 = pathogenic, 4 = likely pathogenic, 3 = variant of uncertain significance. Classification of the variants not present or present but not yet classified in the InSiGHT database is given between brackets, using guidelines provided by <https://www.insight-group.org/criteria/>. Nonsense and frameshift mutations, including large genomic deletions, were classified as pathogenic (class 5). Canonical splice variants and large in-frame genomic deletions were classified as likely pathogenic (class 4). Additional evidence that suggests pathogenicity for variants that could not be classified a priori as (likely) pathogenic is provided in supplementary table S2.

Supplementary table 2. Additional evidence that suggests pathogenicity for one PMS2 variants

location	PMS2 variant ^a	type of variant	number of families (this study)	Evidence suggestive for pathogenicity ^b
Exon 4	c.319C>T p.Arg107Trp	missense	1 (Netherlands)	<ul style="list-style-type: none"> • MMR-deficiency shown by in vitro MMR assay (van der Klift et al., 2016) • Incomplete aberrant splicing (van der Klift et al., 2015) • In trans with pathogenic PMS2 variant in a CMMRD patient (van der Klift et al., 2016)

^aVariant nomenclature according to HGVS guidelines (<http://varnomen.hgvs.org/>), with reference to NM_000535.5 for PMS2.

^b data on conservation, splice prediction, functional predictions (PolyPhen-2, SIFT, aGVGD, MutationTaster), presence in control population databases (ExAC, ESP, 1000G) and in the ClinVar archive were obtained through Alamut Visual v.2.6, last accessed on 23-12-2017.

Abbreviations: MMR = mismatch repair; CMMRD = constitutional mismatch repair deficiency; MLA = multifactorial likelihood analysis; LR = likelihood ratio; AA = amino acid

References

- Pearlman et al., 2017, *JAMA Oncol* 3: 464
 van der Klift et al., 2015, *Mol Genet Genomic Med* 3:327–345
 van der Klift et al., 2016, *Hum Mutat* 37:1162–1179
 Johannesma et al., 2011, *Clin Genet* 80:243–255
 Miyaki et al., 1997
 Deschênes et al., 2007 *Cancer Lett* 249(2):148-56
 Drost et al., 2013, *Hum Mutat* 34:1477–1480
 van Oers et al., 2010, *Proc Natl Acad Sci U S A* 107(30):13384-9.
 Lagerstedt-Robinson et al., 2016, *Oncol Rep* 36(5):2823-2835
 González-Acosta et al., 2017, *Fam Cancer* 16(4):501-507
 Suerink et al., 2018, *Clin Genet* 93(1):134-137
 Guerrette et al., 1999, *J Biol Chem* 274(10):6336-41
 Gueneau et al., 2013, *Nat Struct Mol Biol* 20(4):461-8